Eli Lilly Says Proposed U.S. BIOSECURE Act Would Affect Pharmaceutical Supply Chain Elements; Currently Do Not See It To Have Material Impact On Business
礼来公司表示,拟议的美国生物安全法案将影响药品供应链要素;目前认为该法案不会对业务产生实质性影响
Eli Lilly Says Proposed U.S. BIOSECURE Act Would Affect Pharmaceutical Supply Chain Elements; Currently Do Not See It To Have Material Impact On Business
礼来公司表示,拟议的美国生物安全法案将影响药品供应链要素;目前认为该法案不会对业务产生实质性影响
使用浏览器的分享功能,分享给你的好友吧